Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 397

1.

The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.

Sivgin S, Karakus E, Kaynar L, Kurnaz F, Pala C, Keklik M, Zararsiz G, Solmaz M, Eser B, Cetin M, Unal A.

Transfus Apher Sci. 2013 Jun;48(3):315-20. doi: 10.1016/j.transci.2013.04.007. Epub 2013 Apr 20.

PMID:
23611684
2.

Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.

Sivgin S, Karakus E, Keklik M, Zararsiz G, Solmaz M, Kaynar L, Eser B, Cetin M, Unal A.

Transfus Apher Sci. 2016 Jun;54(3):410-5. doi: 10.1016/j.transci.2016.03.003. Epub 2016 Mar 24.

PMID:
27052362
3.

Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.

Martino M, Recchia AG, Moscato T, Fedele R, Neri S, Gentile M, Alati C, Vincelli ID, Piro E, Penna G, Musolino C, Ronco F, Molica S, Morabito F.

Cytotherapy. 2015 Oct;17(10):1485-93. doi: 10.1016/j.jcyt.2015.05.010. Epub 2015 Jul 15.

PMID:
26188967
4.

Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.

Lor KW, Helmons PJ, Belew H, Lane JR, Ball ED.

Pharmacotherapy. 2012 Jul;32(7):596-603. doi: 10.1002/j.1875-9114.2012.01096.x.

PMID:
22760691
5.
6.

Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.

Reményi P, Gopcsa L, Marton I, Réti M, Mikala G, Pető M, Barta A, Bátai A, Farkas Z, Borbényi Z, Csukly Z, Bodó I, Fábián J, Király A, Lengyel L, Piukovics K, Torbágyi E, Masszi T.

Adv Ther. 2014 Apr;31(4):451-60. doi: 10.1007/s12325-014-0114-z. Epub 2014 Apr 1.

PMID:
24687301
7.

Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.

Danylesko I, Sareli R, Bloom-Varda N, Yerushalmi R, Shem-Tov N, Shimoni A, Nagler A.

Biol Blood Marrow Transplant. 2016 Feb;22(2):277-83. doi: 10.1016/j.bbmt.2015.08.033. Epub 2015 Sep 4.

8.

Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.

Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ, Hsu FJ, Bridger G, Bolwell BJ.

Biol Blood Marrow Transplant. 2012 Oct;18(10):1564-72. doi: 10.1016/j.bbmt.2012.05.017. Epub 2012 Jun 6.

9.

Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs.

Ria R, Gasparre T, Mangialardi G, Bruno A, Iodice G, Vacca A, Dammacco F.

Bone Marrow Transplant. 2010 Feb;45(2):277-81. doi: 10.1038/bmt.2009.150. Epub 2009 Jul 6.

PMID:
19584820
10.

Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation.

Schmitt M, Publicover A, Orchard KH, Görlach M, Wang L, Schmitt A, Mani J, Tsirigotis P, Kuriakose R, Nagler A.

Theranostics. 2014 Jan 23;4(3):280-9. doi: 10.7150/thno.7752. eCollection 2014. Review.

11.

A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization.

Manko J, Walter-Croneck A, Jawniak D, Grzasko N, Gorska-Kosicka M, Cioch M, Dmoszynska A.

Pharmacol Rep. 2014 Apr;66(2):239-42. doi: 10.1016/j.pharep.2013.09.005. Epub 2014 Mar 3.

PMID:
24911076
12.

Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.

Samaras P, Pfrommer S, Seifert B, Petrausch U, Mischo A, Schmidt A, Schanz U, Nair G, Bargetzi M, Taverna C, Stupp R, Stenner-Liewen F, Renner C.

Biol Blood Marrow Transplant. 2015 Jan;21(1):74-80. doi: 10.1016/j.bbmt.2014.09.020. Epub 2014 Sep 30.

14.

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.

Elayan MM, Horowitz JG, Magraner JM, Shaughnessy PJ, Bachier C.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1921-5. doi: 10.1016/j.bbmt.2015.05.024. Epub 2015 May 30.

15.

Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.

Wang S, Nademanee A, Qian D, Dagis A, Park HS, Fridey J, Smith E, Snyder D, Somlo G, Stein A, Rosenthal J, Falk P, Kogut N, Palmer J, Gaal K, Kim Y, Bhatia R, Yuan S, Kay C, Weiss L, Forman S.

Transfusion. 2007 Dec;47(12):2207-16. Epub 2007 Aug 21.

PMID:
17714420
16.

Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective study of 126 patients.

Lefrère F, Bernard M, Audat F, Cavazzana-Calvo M, Belanger C, Hermine O, Arnulf B, Buzyn A, Varet B.

Leuk Lymphoma. 1999 Nov;35(5-6):501-5.

PMID:
10609787
19.

Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.

Bhutani D, Zonder J, Valent J, Tageja N, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Lum L, Ratanatharathorn V, Uberti J, Abidi MH.

Support Care Cancer. 2013 Sep;21(9):2437-42. doi: 10.1007/s00520-013-1808-5. Epub 2013 Apr 17.

20.

Supplemental Content

Support Center